The Government of India has officially announced a significant change in API Import Duty India 2025, effective from August. This move is a part of the larger policy to promote domestic manufacturing of Active Pharmaceutical Ingredients (APIs) under the Atmanirbhar Bharat initiative. The updated duty structure introduces increased import tariffs on over 40 high-demand APIs, aimed at reducing dependency on imports—particularly from China—and strengthening India’s pharmaceutical supply chain resilience.
With the rising cost of imported APIs and the growing need for self-sufficiency, this revision is considered one of the boldest steps in the pharma sector in recent years. Manufacturers, bulk drug suppliers, and industry associations have all been notified of the changes well in advance to allow for adjustments and transitions.
In this article, we cover the updated duty rates, the complete list of affected APIs, the expected industry impact, and how the policy aligns with India’s broader pharmaceutical goals.
What Changes in API Import Duty India 2025?
From August 1, 2025, the import duties on a specific group of APIs will increase from the current average of 10% to 25%–35%, depending on the product category. The aim is to discourage import dependency and motivate pharmaceutical companies to procure or produce these APIs domestically.
Highlights of the update:
-
Tariff hike for 40+ high-volume APIs including antibiotics, antivirals, and hormones
-
Special focus on APIs for paracetamol, metformin, ciprofloxacin, and amoxicillin
-
No change in duty for rare or low-volume APIs where domestic capacity is still building
-
Duty exemptions removed from APIs currently under FTA agreements with certain countries
-
Incentives linked to PLI schemes now being rolled out for domestic API units
The Department of Revenue and Ministry of Chemicals and Fertilizers have jointly issued circulars to ensure smooth implementation of the new API Import Duty India 2025 structure.
List of Major APIs Impacted by New Duty Structure
Here’s a snapshot of the most critical APIs now subject to higher import duty rates:
| API Name | Old Duty (%) | New Duty (%) |
|---|---|---|
| Paracetamol | 10% | 25% |
| Amoxicillin | 10% | 30% |
| Metformin | 5% | 25% |
| Ciprofloxacin | 10% | 35% |
| Azithromycin | 5% | 25% |
| Vitamin C (Ascorbic) | 10% | 30% |
| Ibuprofen | 5% | 25% |
| Rifampicin | 10% | 35% |
| Glibenclamide | 5% | 30% |
The revised API Import Duty India 2025 will significantly impact drug pricing structures, encouraging bulk procurement from local sources.
Impact on Indian Pharma Industry
This change is expected to be a turning point for India’s pharmaceutical sector. While some manufacturers may face short-term cost increases due to imported stock already in transit, the medium and long-term effects are largely positive.
Benefits of the duty hike:
-
Revival of domestic API units that were previously underutilized due to cheaper Chinese imports
-
Job creation in chemical and pharma hubs like Gujarat, Himachal Pradesh, and Telangana
-
Higher compliance with environmental standards, as Indian plants are being modernized
-
Reduced exposure to global supply chain disruptions
-
Strengthening of India’s pharma export profile with self-manufactured inputs
While the government assures that the impact on end-consumer pricing will be minimal, pharma companies will be expected to transition towards local sourcing within the next 6–12 months.
Government Support for Smooth Transition
To support this shift, the government is enhancing support under existing schemes alongside the API Import Duty India 2025 revision:
-
Fast-tracking of approvals under the Production Linked Incentive (PLI) Scheme
-
Establishment of new Bulk Drug Parks in Tamil Nadu, Himachal Pradesh, and Andhra Pradesh
-
R&D grants for green chemistry and eco-friendly API production methods
-
Zero duty on import of equipment needed for setting up API manufacturing units
-
Collaboration with PSUs for backward integration
The government has emphasized that its dual focus is on industry health and patient affordability, and policies will continue to balance both.
FAQs
What is the effective date for the API import duty changes in 2025?
The revised API Import Duty India 2025 will be effective from August 1, 2025.
Will this lead to a price increase in common medicines?
Not significantly. Manufacturers are being encouraged to shift sourcing locally, which will stabilize costs in the long run.
Are all APIs affected by the duty change?
No. Only high-demand APIs with known domestic manufacturing potential are targeted. Rare or low-volume APIs are excluded for now.
How is the government supporting local API manufacturers?
Through PLI schemes, bulk drug parks, and import duty exemptions on manufacturing equipment.
Can small-scale pharma companies adapt to these changes?
Yes. The government is offering financial incentives and regulatory support to help MSMEs transition to local API procurement.
Click here to know more.